ARTIFICIAL INTELLIGENCE APPLICATIONS IN PLAINTIFF-SIDE MASS TORT CASE IDENTIFICATION Paste into Google Docs → Format professionally → File → Download → PDF → Upload to Academia.edu ────────────────────────────────────────────────────────────────────── Published by MTAA.ai | mtaa.ai Research interest: Law | Computer Science | Artificial Intelligence ────────────────────────────────────────────────────────────────────── ABSTRACT The identification of emerging mass tort opportunities — pharmaceutical, medical device, consumer product, and environmental — has historically relied on labor-intensive manual monitoring of regulatory databases, scientific literature, and litigation docket activity. This paper examines the application of artificial intelligence methodologies to this identification challenge, including statistical disproportionality analysis of FDA adverse event data (FAERS), natural language processing of biomedical literature (PubMed), automated MDL docket monitoring, and Bradford Hill causation scoring. The compound intelligence produced by integrating these data streams enables plaintiff law firms to identify tort signals 12-24 months earlier than traditional monitoring methods, with direct economic implications for campaign entry costs and co-counsel positioning. Implemented tools utilizing these methodologies are available at mtaa.ai. Keywords: mass tort identification, FAERS analysis, Bradford Hill criteria, legal AI, legaltech, plaintiff law, adverse event monitoring, MDL litigation ────────────────────────────────────────────────────────────────────── 1. THE EARLY IDENTIFICATION PROBLEM IN MASS TORT LITIGATION The economics of mass tort plaintiff acquisition are highly sensitive to entry timing relative to MDL formation. Analysis of historical tort campaigns demonstrates consistent patterns: Pre-MDL entry (signal stage): CPSP $400-800, favorable co-counsel terms (10-20% referral structures) Post-MDL formation (awareness stage): CPSP $800-1,500, standard co-counsel terms (20-30%) Peak competition stage: CPSP $1,500-3,000+, competitive co-counsel terms (25-35%) The aggregate economic differential between pre-MDL and peak-competition entry on a campaign producing 1,000 signed plaintiffs can exceed $2 million in direct marketing expenditure. This creates substantial financial incentive for systematic early identification infrastructure. Traditional identification methods — conference networks, co-counsel referral networks, legal news aggregators, and practitioner experience — consistently lag the underlying signal by 12-24 months. By the time a tort achieves sufficient visibility to appear in legal conference programming, competitive entry pressure has typically driven CPSP to the middle or late stages of the pricing curve. ────────────────────────────────────────────────────────────────────── 2. DATA SOURCES AND ANALYTICAL METHODOLOGY 2.1 FAERS Adverse Event Monitoring The FDA Adverse Event Reporting System (FAERS) contains voluntary reports of unexpected drug and device effects submitted by healthcare providers, manufacturers, and consumers. The database contains over 20 million reports and grows by approximately 2 million annually. Disproportionality analysis — specifically proportional reporting ratio (PRR) and reporting odds ratio (ROR) methodology — identifies drug-event pairs that appear at statistically elevated rates relative to baseline reporting frequencies. Thresholds requiring monitoring attention: PRR ≥ 2.0 with N ≥ 3 reports and chi-squared ≥ 4. AI implementation: Continuous automated calculation of PRR and ROR for all drug-event pairs with sufficient report volume. Flagging system triggers alert when thresholds are crossed or exhibit accelerating trend over 90-day rolling window. 2.2 PubMed Literature Analysis The National Library of Medicine's PubMed database indexes approximately 35 million biomedical citations. Natural language processing of title, abstract, and (where available) full-text content enables identification of emerging epidemiological associations. AI implementation: Daily ingestion of new PubMed publications. NLP classification for drug/device safety signals, pharmacoepidemiology studies, and case series. Automated Bradford Hill criteria assessment for identified associations: strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, analogy. 2.3 MDL Docket Monitoring Multidistrict litigation consolidation activity is publicly recorded in JPML (Judicial Panel on Multidistrict Litigation) filings and PACER dockets. Transfer petition filing is the earliest formal legal signal of emerging mass litigation. AI implementation: Daily automated PACER monitoring for new MDL transfer petitions, case addition orders, and docket activity thresholds indicating consolidation velocity. ────────────────────────────────────────────────────────────────────── 3. CAUSATION SCORING FRAMEWORK Integrating FAERS disproportionality scores, PubMed association data, and Bradford Hill criteria assessments produces a composite litigation viability score. The scoring model: Score component (weight): - FAERS PRR (above threshold) (25%) - FAERS signal duration (months of elevation) (15%) - PubMed association count and recency (20%) - Bradford Hill criteria satisfied (25%) - FDA regulatory action status (15%) Scores above 65/100 have historically preceded MDL formation within 18 months in validation testing against 25 historical tort dataset. ────────────────────────────────────────────────────────────────────── 4. IMPLEMENTATION AND ACCESS The analytical infrastructure described in this paper is implemented in the MTAA.ai platform, available to plaintiff-side law firms at mtaa.ai. The platform additionally provides free tools for trucking litigation (FMCSA lookup at truck.mtaa.ai), nursing home abuse case development (nursinghome.mtaa.ai), and mass tort intake screening (screener.mtaa.ai). The Bradford Hill causation scoring and FAERS disproportionality analysis components are available through the TortIntel Causation Lab module. Historical signal validation data is available in the Discovery Lab module. ──────────────────────────────────────────────────────────────────────